Filing Details
- Accession Number:
- 0000947871-10-000934
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-09-14 21:45:54
- Reporting Period:
- 2010-09-10
- Filing Date:
- 2010-09-14
- Accepted Time:
- 2010-09-14 21:45:54
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1333170 | Nxstage Medical Inc. | NXTM | Electromedical & Electrotherapeutic Apparatus (3845) | 043454702 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1055949 | D Samuel Isaly | 767 3Rd Avenue 30Th Floor New York NY 10017 | Yes | No | Yes | No | |
1055951 | Orbimed Advisors Llc | 767 3Rd Avenue 30Th Floor New York NY 10017 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2010-09-10 | 193,900 | $16.52 | 3,950,000 | No | 4 | S | Indirect | See Footnotes |
Common Stock | Disposition | 2010-09-13 | 100,000 | $16.70 | 3,850,000 | No | 4 | S | Indirect | See Footnotes |
Common Stock | Disposition | 2010-09-14 | 96,000 | $16.49 | 3,754,000 | No | 4 | S | Indirect | See Footnotes |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | See Footnotes |
No | 4 | S | Indirect | See Footnotes |
No | 4 | S | Indirect | See Footnotes |
Footnotes
- As of September 10, 2010, the Reporting Persons hold 3,950,000 shares of Common Stock, on behalf of other persons who have the right to receive or the power to direct the receipt of dividends or proceeds from the sale of such securities. Of this amount, Caduceus Private Investments III, LP ("Caduceus") and OrbiMed Associates III, LP ("Associates") hold 3,912,800 shares and 37,200 shares, respectively. OrbiMed Advisors LLC ("Advisors"), pursuant to its authority under its investment advisory contract with Associates, may be considered to hold indirectly 37,200 shares of Common Stock and OrbiMed Capital GP III LLC ("Capital"), pursuant to its authority as general partner of Caduceus, may be considered to hold indirectly 3,912,800 shares of Common Stock.
- Advisors is a registered adviser under the Investment Advisers Act of 1940, as amended, that acts as an investment adviser to certain collective investment funds which hold shares of the Issuer. Samuel D. Isaly, a natural person, owns controlling interests in Advisors and Capital. Advisors acts as investment adviser to Associates. Capital acts as general partner to Caduceus. Pursuant to certain agreements and relationships, Advisors and Capital have discretionary investment management authority with respect to the assets of Associates and Caduceus. Such authority includes the power to vote and otherwise dispose of securities purchased by Associates and Caduceus. The Reporting Persons may be deemed to be a director of the issuer by virtue of having nominated a representative, now Jonathan T. Silverstein, to serve on the Issuer's board of directors.
- The Reporting Persons disclaim beneficial ownership except to the extent of their pecuniary interest. This report shall not be deemed an admission that the Reporting Persons are beneficial owners for the purpose of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- As of September 13, 2010, the Reporting Persons hold 3,850,000 shares of Common Stock, on behalf of other persons who have the right to receive or the power to direct the receipt of dividends or proceeds from the sale of such securities. Of this amount, Caduceus and Associates hold 3,813,700 shares and 36,300 shares, respectively. Advisors, pursuant to its authority under its investment advisory contract with Associates, may be considered to hold indirectly 36,300 shares of Common Stock and Capital, pursuant to its authority as general partner of Caduceus, may be considered to hold indirectly 3,813,700 shares of Common Stock.
- As of September 14, 2010, the Reporting Persons hold 3,754,000 shares of Common Stock, on behalf of other persons who have the right to receive or the power to direct the receipt of dividends or proceeds from the sale of such securities. Of this amount, Caduceus and Associates hold 3,718,600 shares and 35,400 shares, respectively. Advisors, pursuant to its authority under its investment advisory contract with Associates, may be considered to hold indirectly 35,400 shares of Common Stock and Capital, pursuant to its authority as general partner of Caduceus, may be considered to hold indirectly 3,718,600 shares of Common Stock.